Prevalence and Factors Associated with Treatment Failure during Antiretroviral Therapy Atbobo-Dioulasso University Teaching Hospital (Burkina Faso) (2008- 2013)

Research Article

Austin J HIV/AIDS Res. 2016; 3(2): 1027.

Prevalence and Factors Associated with Treatment Failure during Antiretroviral Therapy Atbobo-Dioulasso University Teaching Hospital (Burkina Faso) (2008- 2013)

Zoungrana J1,3*, Poda A1,3, Sondo KA4,5, Diallo I4,5, Bado G³, Ouedraogo AS¹, Koura M¹, Tougouma JB¹, Hema A³, Kaboré NF³, Soré I³, Yaméogo I³, Sawadogo AB3,4, Ouedraogo WT6, Savadogo M4,5, and Ouedraogo MS1,2

¹Polytechnic University of Bobo-Dioulasso, Higher Institute of Health Sciences, Bobo-Dioulasso, Burkina Faso

²Department of Internal Medicine of the University Hospital Souro Sanou, Bobo-Dioulasso, Burkina Faso

³Department of Infectious Diseases and Day hospital CHU Souro Sanou, Bobo-Dioulasso, Burkina Faso

4University of Ouagadougou, Training and Research Unit in Health Sciences (UFR / SDS)

5Service of Infectious Diseases at Yalgado Ouedraogo Hospital, Ouagadougou, Burkina Faso

6Regional Health Directorate of High Basins, Ministry of Health, Burkina faso

*Corresponding author: Zoungrana Jacques, Infectious Diseases and Day Hospital Service, Polytechnic University of Bobo-Dioulasso, Higher Institute of Health Sciences , 03 BP 4178 Bobo-Dioulasso 03, Burkina Faso

Received: June 13, 2016; Accepted: July 27, 2016; Published: July 29, 2016

Abstract

Summary: The objective of this study was to determine the prevalence and factors associated with therapeutic failure.

Materials and Methods: We have conducted a retrospective and analytical cohort study from January 2008 to December 2013, targeting out-patients under ambulatory consultation at the day hospital of Sanou Souro Teaching Hospital (SSTH). Were included in the study the entire patient’s sero positive for HIV-1 and under anti-retroviral treatment (ARVT), regularly followed in the active file of the Day hospital for at least twelve months and who have achieved a CD4 rate and a viral load in the systematic review of HIV infection.

Results: During the study period, 512 patients met our inclusion criteria. The median age was 37.5 years with (IQ 32.2 to 45.1) a sex ratio of 0.38 in favor of females. An opportunistic infection was the cause of the serology discovery with 57.6% of patients. According to WHO classification, 42.2% of patients were at stage 3 of WHO. At the start of the treatment, the median number of lymphocytes T CD4 was 179cells/μl (IQR: 85-258). The scheme two nucleoside reverse transcriptase inverse (NRTIs) and a non-nucleotide reverse transcriptase inhibitor (NNRTI) was the most used with 93.6%. The prevalence of treatment failure was (6.4%). Age and CD4 rate inferior to 200/mm3 at the start of the treatment were associated with treatment failure.

Conclusion: This study shows that treatment failure is common (6.4%) in the active line of the day hospital of Bobo-Dioulasso. A significant association between older age and a CD4 rate inferior to 200mm3 at the start of the treatment was recorded.

Keywords: Prevalence; Treatment failure; ARVT; Burkina Faso

Abbreviations

AIDS: Acquired Immune Deficiency Syndrome; ARV: Antiretroviral Drugs; ARVT: Antiretroviral Drug treatment; BMI: Body Mass Index; CD4: Cluster+D6:D28 of Differentiation 4; CHUSS: University Teaching Hospital Souro Sanou; ESOPE: Together for a Therapeutic Solidarity Hospital in Network; HDJ: Day hospital; HIV: Human Immunodeficiency Virus; IQR: Inter Quartile Range; M0: 0month; M12: 12-Months; NNRTI: Non-nucleotide Reverse Transcriptase Inhibitor; NRTIs: Nucleoside Reverse Transcriptase Inverse; WHO: World Health Organization

Introduction

Sub-Saharan Africa remains the area the most affected by HIV infection with 25.8 million people affected [1]. Many countries have set up strategies to stop the advance of the infection and improve patients’ comfort. These strategies focus on the availability of effective antiretroviral (ARV) drugs, whose use has significantly reduced mortality from HIV [2,3]. Indeed, these molecules cause a drop in viral load and consequently a restoration of immunity. Combined antiretroviral therapies has changed the management of HIV infection and transformed the perception of HIV infection which has become a chronic disease [4,5]. For that reason, new problems have emerged, especially treatment failure.

In low income countries, there is little data on treatment failure and associated factors [6-9]. Several authors such as Fibriani in Indonesia [10] and Ahoua in Uganda [11] reported failure rates in their cohort studies with respectively 9.1% and 10.9%. In Burkina Faso, particularly at the day hospital (HDJ) of Bobo Dioulasso, there is, to our knowledge, little study on therapeutic failures. The objective of this study was to determine the prevalence and the factors associated with treatment failure.

Materials and Methods

We have conducted a retrospective and analytical cohort study from January 2008 to December 2012, targeting out-patients under ambulatory consultation at the Day Hospital (HDJ) of University Teaching Hospital Sanou Souro (CHU SS) of Bobo-Dioulasso which is the second capital of Burkina Faso after Ouagadougou.

Were included in the study all the patients HIV-1 positive under ARV treatment (ARVT) regularly followed in the active file of the HDJ for at least twelve months (M12) and who have achieved a CD4 proportion and a viral load in systematic checkup of HIV infection monitoring. For each selected patient, we have collected data during medical consultations thanks to ESOPE software (Together for Therapeutic Solidarity Hospital In Network) and in the medical record of patients. These data included socio-demographic, clinical, and biological data at the start of the antiretroviral therapy, the implementation of the treatment, the visiting dates of immunevirological monitoring and the observance of ARVT (LOGONE software). The data on the level of observance of our patients were extracted from ACCESS database after consulting observance support informed by nurses.

Treatment failure was defined as two successive measurements of viral load> 1000 copies /ml after a virological success. If the second viral load> 1000 copies/ml was missing, the following criteria were used to define treatment failure: a single viral load>1000 copies/ ml accompanied by an immunological failure as defined by WHO [12] or one viral load> 5000 copies /ml. A simple virologic rebound was defined as a viral load>1000 copies/ml without further criteria of virologic failure. Observance was measured by the ratio between the number of prescriptions made and the theoretical amount of expected prescriptions (which correspond to the number of months of treatment follow-up). The patient was considered as observing when this coefficient was strictly superior to 0.95. The management of treatment failure was based on enhancing observance and therapeutic change according to WHO algorithm for the adult [12].

The data collected from ESOPE database were transferred to Epi- Info 2000 version 3.5 for analysis. Demographic, clinical, therapeutic characteristics observance data, the evolutionary and biological profile of patients at inclusion (M0) and at month 12 were described basing on the descriptive statistics of variables. Quantitative variables were described by their medians and inter quartile intervals (IQR). All risk factors were analyzed through logistic regression. Were included in the model all the factors with a p value<0.25 in exploratory analysis. Variables maintained in the model were those whose p value was <0.05, as determined significance threshold in the overall analysis. In uni varied analysis, Pearson chi 2 test was used to compare proportions and Student’s test was used to test the equality of two averages in uni varied analysis.

Results

Epidemiological and clinical characteristics

During the study period, 2250 persons infected with HIV-1 were put on ARVT treatment between January 2008 and December 2013, of which 512 (4.4%) met our inclusion criteria. The median age was 37.5 years with (IQR 32.2 to 45.1). The Socio-demographic and clinical characteristics of the patients at enrollment are shown in Table 1.

Patients with married life represented (53.3%). Most patients lived within 10 kilometer from the center. Unschooled patients were 239, that is 46.7%. An opportunistic infection was the cause of the serology discovery of 57.6% of patients (n = 295). The median of BMI was 20.6 kg /m² (IQR 18.3 to 23.4) with extremes of 11.2 and 40.0 kg /m². The majority (58%; n = 270) had a normal body mass index. According to WHO classification 2006 (42.2%) of patients were at WHO stage 3. At the start of treatment, the median number T CD4 lymphocytes was 179 cells/μl (IQR: 85-258) with extremes of 1 and 399 cells/μl. Hemoglobin rate was not given with 13 patients. Hemoglobin median rate was 10.9 g /dl (IQR: 9.6 to 12) with extremes from 5.9 to 14,9g / dl; 31.5% (n = 158) of patients had a hemoglobin level inferior or equal to 10g/dl at the start of treatment. The median blood glucose (glycemia) was 4.9 mmol / l (IQR: 4.6 to 5.5) with extremes from 3.3 to 6,7mmol /l. The median of creatinine was 70mmol /l (IQR: 60 to 81) with extremes from 46 to 308μmol/l. The median of alanine aminotransferase (ALAT) was 19.5u /l (IQR: 12-30) with extremes from 12 to 30u/l.

Therapeutic characteristics

The median duration of the treatment was 2.7 years (IQR: 1.7 to 4.2) with extremes from 1.2 years to 4.9 years. The scheme two nucleoside reverse transcriptase inverse (NRTIs) and a nonnucleotide reverse transcriptase inhibitor (NNRTI) was the most used with 93.6% (479). Therapeutic combinations containing zidovudine (AZT) were the most prescribed 63.9% (327). The most used treatment protocols were zidovudine/lamivudine/nevirapine (AZT/3TC/NVP) with a frequency of 31.8% and (zidovudine /lamivudine/efavirenz) (AZT/3TC/EFV) prescribed for 28.3% of patients at treatment start. Within 12-month follow-up, the level of patients’ observance to ARV was assessed 6 times and 63.7% of patients were found to observant to all the six assessments. The proportion of observing patients was increasing with ARV exposure time; the maximum of observing patients was noted at the 12th month (93.2%) (Figure 1). In 12 months of follow up, the median number of CD4 T lymphocytes increased from 179 to 312 cells / μll, that is a gain of 133 cells.